Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ALLARITY THERAPEUTICS INC (ALLR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.98-9.64%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ALLR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise at least $16.93M in capital by 2026-Q1 | A primary condition in ALLARITY THERAPEUTICS INC's published investment case. The stated target is >= 16.93 million USD. | Improving | capital raised falls below $16.93M by 2026-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder: the business is loss-making and its risk level is high. The multi-year thesis is in a watch state, with management continuing stenoparib trials but overall confidence low.
The evidence snapshot gives no direct valuation measure or specific account of market expectations, so whether the shares look cheap or expensive versus peers is unclear. The main visible expectation is that clinical progress and a broader Healthcare sector tailwind can support the story, but that tailwind could fade if sector leaders weaken.
Near term, management remains focused on Phase 2 stenoparib trials for ovarian and lung cancer; cash and restricted cash reached $26.9 million by 2026-Q2, and an August earnings beat was reported. Still, the company is loss-making, recent financial performance is below its industry cohort, and a material agreement termination was reported on 2026-10-30. The diagnostic program has mixed progress, while the expanded laboratory work is early and has no linked financial metrics yet.
Over the multi-year view, the central swing factor is whether the clinical trials produce progress toward the stated regulatory goals. The companion diagnostic and laboratory expansion may support that work, but their contribution remains uncertain. Near term, a weakening jobs trend could deepen recession concerns, while results from VRTX, REGN, and MRNA may signal whether the Healthcare sector tailwind continues or fades.
For the next one to three years, ALLR's thesis rests on clinical execution rather than proven earnings, with high risk and low confidence. Recent signals are mixed, so meaningful evidence from trials and continued funding capacity matter most. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in ALLARITY THERAPEUTICS INC's published investment case. The stated target is >= -4.5 million USD. |
| Recovered |
| cash burn stays worse than negative $4.5M beyond 2026-Q1 |
Cash from operations: $-2.564M FY2026-Q2; GAAP. Published target: >= -4.5 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-2,564,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: “The Company used $2.6 million of cash in operating activities during the quarter.” “The Company used $2.6 million of cash in operating activities during the quarter.” Delivery assessment Nov 4, 2026 |
Implement management changes to support company strategy | Management changes aim to support the strategy. | Intact | no meaningful management changes by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating income improves to negative $2.7M or better | Operating income improved by $4.6M. | Broken | operating income remains below negative $2.7M beyond 2026-Q1 | Operating income: $-2.671M FY2026-Q2; GAAP. Published target: >= -2.7 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-2,671,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: “The Company used $2.6 million of cash in operating activities during the quarter.” “The Company used $2.6 million of cash in operating activities during the quarter.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.97 → $-0.86 · observed estimates
$0.09B → $0.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-07-25 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-07-26 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-07-27 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-07-28 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-07-29 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-07-30 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-07-31 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-01 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-02 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-03 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-04 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-05 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-06 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-07 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-08 | $-0.97 | $0 | 1 / 1 |
| 2026-08-09 | $-0.97 | $0 | 1 / 1 |
| 2026-08-10 | $-0.97 | $0 | 1 / 1 |
| 2026-08-11 | $-0.97 | $0 | 1 / 1 |
| 2026-08-12 | $-0.97 | $0 | 1 / 1 |
| 2026-08-13 | $-0.97 | $0 | 1 / 1 |
| 2026-08-14 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-15 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-16 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-17 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-18 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-19 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-20 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-21 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-22 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-23 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-24 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-25 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-26 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-27 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-28 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-29 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-30 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-08-31 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-01 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-02 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-03 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-04 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-05 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-06 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-07 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-08 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-09 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-10 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-11 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-12 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-13 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-14 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-15 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-16 | $-0.97 | $85,865,000 | 1 / 1 |
| 2026-09-17 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-18 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-19 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-20 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-21 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-22 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-23 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-24 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-25 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-26 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-27 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-28 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-29 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-09-30 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-01 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-02 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-03 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-04 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-05 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-06 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-07 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-08 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-09 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-10 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-11 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-12 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-13 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-14 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-15 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-16 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-17 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-18 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-19 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-20 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-21 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-22 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-23 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-24 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-25 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-26 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-27 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-28 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-29 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-30 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-10-31 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-11-01 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-11-02 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-11-03 | $-0.86 | $85,865,000 | 1 / 1 |
| 2026-11-04 | $-0.86 | $85,865,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.